Bolt Biotherapeutics, Inc. Comprehensive Income
Bolt Biotherapeutics, Inc. (BOLT) reported Comprehensive Income of -$7.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$7.75M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$7.23M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$6.64M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.15M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$33.49M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$63.06M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$68.24M.
- Bolt Biotherapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$88.70M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.75M 10-Q · filed 2026-08-11 | -$14.99M 10-Q · filed 2026-08-11 | -$21.63M derived: sum of 3 quarters · filed 2026-08-11 | -$28.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$7.23M 10-Q · filed 2026-05-12 | -$13.88M derived: sum of 2 quarters · filed 2026-05-12 | -$21.02M derived: sum of 3 quarters · filed 2026-05-12 | -$29.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$13.79M derived: sum of 2 quarters · filed 2026-03-12 | -$22.40M derived: sum of 3 quarters · filed 2026-08-11 | -$33.49M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$7.15M 10-Q · filed 2025-11-12 | -$15.76M derived: sum of 2 quarters · filed 2026-08-11 | -$26.85M 10-Q · filed 2025-11-12 | -$42.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$8.61M 10-Q · filed 2026-08-11 | -$19.70M 10-Q · filed 2026-08-11 | -$35.75M derived: sum of 3 quarters · filed 2026-08-11 | -$50.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$11.10M 10-Q · filed 2026-05-12 | -$27.14M derived: sum of 2 quarters · filed 2026-05-12 | -$42.07M derived: sum of 3 quarters · filed 2026-05-12 | -$63.27M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$16.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$30.97M derived: sum of 2 quarters · filed 2026-03-12 | -$52.17M derived: sum of 3 quarters · filed 2026-03-12 | -$63.06M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$14.93M 10-Q · filed 2025-11-12 | -$36.13M derived: sum of 2 quarters · filed 2025-11-12 | -$47.01M 10-Q · filed 2025-11-12 | -$64.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$21.20M 10-Q · filed 2025-08-14 | -$32.09M 10-Q · filed 2025-08-14 | -$49.78M derived: sum of 3 quarters · filed 2025-08-14 | -$65.98M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$10.88M 10-Q · filed 2025-05-12 | -$28.58M derived: sum of 2 quarters · filed 2025-05-12 | -$44.78M derived: sum of 3 quarters · filed 2025-05-12 | -$62.83M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$33.89M derived: sum of 2 quarters · filed 2025-03-24 | -$51.95M derived: sum of 3 quarters · filed 2025-03-24 | -$68.24M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$16.20M 10-Q · filed 2024-11-12 | -$34.25M derived: sum of 2 quarters · filed 2024-11-12 | -$50.55M 10-Q · filed 2024-11-12 | -$69.76M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$18.05M 10-Q · filed 2024-08-13 | -$34.35M 10-Q · filed 2024-08-13 | -$53.55M derived: sum of 3 quarters · filed 2024-08-13 | -$75.22M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$16.30M 10-Q · filed 2024-05-14 | -$35.50M derived: sum of 2 quarters · filed 2024-05-14 | -$57.17M derived: sum of 3 quarters · filed 2024-05-14 | -$80.24M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$19.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$40.87M derived: sum of 2 quarters · filed 2024-03-21 | -$63.94M derived: sum of 3 quarters · filed 2024-03-21 | -$88.70M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$21.66M 10-Q · filed 2023-11-09 | -$44.74M derived: sum of 2 quarters · filed 2023-11-09 | -$69.49M 10-Q · filed 2023-11-09 | -$96.93M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$23.07M 10-Q · filed 2023-08-07 | -$47.82M 10-Q · filed 2023-08-07 | -$75.26M derived: sum of 3 quarters · filed 2023-08-07 | -$98.67M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$24.75M 10-Q · filed 2023-05-11 | -$52.19M derived: sum of 2 quarters · filed 2023-05-11 | -$75.60M derived: sum of 3 quarters · filed 2023-05-11 | -$99.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$27.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$50.85M derived: sum of 2 quarters · filed 2023-03-29 | -$74.39M derived: sum of 3 quarters · filed 2023-03-29 | -$98.91M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$23.41M 10-Q · filed 2022-11-10 | -$46.95M derived: sum of 2 quarters · filed 2022-11-10 | -$71.47M 10-Q · filed 2022-11-10 | -$102.51M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$23.54M 10-Q · filed 2022-08-10 | -$48.06M 10-Q · filed 2022-08-10 | -$79.10M derived: sum of 3 quarters · filed 2022-08-10 | -$89.10M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$24.52M 10-Q · filed 2022-05-12 | -$55.55M derived: sum of 2 quarters · filed 2022-05-12 | -$65.56M derived: sum of 3 quarters · filed 2022-05-12 | -$76.60M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$31.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$41.04M derived: sum of 2 quarters · filed 2022-03-30 | -$52.09M derived: sum of 3 quarters · filed 2022-03-30 | -$60.73M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$10.00M 10-Q · filed 2021-11-09 | -$21.05M derived: sum of 2 quarters · filed 2021-11-09 | -$29.69M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$11.05M 10-Q · filed 2021-08-12 | -$19.69M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$8.64M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |